<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04682704</url>
  </required_header>
  <id_info>
    <org_study_id>12708</org_study_id>
    <nct_id>NCT04682704</nct_id>
  </id_info>
  <brief_title>The Effect of Different Low-Level Tragus Stimulation Parameters On Autonomic Nervous System Function</brief_title>
  <acronym>LLT-SPANS</acronym>
  <official_title>The Effect of Different Low-Level Tragus Stimulation Parameters On Autonomic Nervous System Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low level transcutaneous vagus nerve stimulation (LLTS) involves delivery of electrical&#xD;
      impulses transcutaneously at the auricular branch of vagus nerve and it has been shown to&#xD;
      have anti-inflammatory and anti-arrhythmic effects. In previous studies from our laboratory,&#xD;
      we found that LLTS significantly suppressed atrial fibrillation (AF) inducibility and&#xD;
      decreased AF duration. The anti-arrhythmic effects of LLTS were similar to those delivered to&#xD;
      the cervical VN trunk. LLTS for just one hour significantly shortened the AF duration and&#xD;
      decreased inflammatory cytokines. We have also shown that LLTS leads to favorable heart rate&#xD;
      variability (HRV) changes and cardiac mechanics in patients with diastolic dysfunction. These&#xD;
      results support the use of LLTS as a novel non-pharmacological, non-ablative treatment&#xD;
      modality for AF and possibly other inflammatory conditions. However, the optimal stimulation&#xD;
      parameters of LLTS remain to be determined.&#xD;
&#xD;
      In this study, we aim to examine the effect of 2 different frequencies (5Hz and 20Hz) and 2&#xD;
      different amplitudes (50% below the pain threshold and 1mA below the pain threshold) of LLTS&#xD;
      on heart rate variability with deep breathing (HRVdb), mental arithmetic stress test (MAST),&#xD;
      frequency domain measures of heart rate variability (HRV) and brain stem evoked potentials&#xD;
      (BSEVP) in healthy volunteers and patients with AF or heart failure with preserved ejection&#xD;
      fraction (HFpEF). HRV is a marker of vagus nerve activity and can be easily measured by&#xD;
      software calculating the distance between consecutive R waves on the ECG. BSEVP are a&#xD;
      surrogate for the central projections of the vagus nerve. Patients will be randomized into 4&#xD;
      groups in a 2x2 factorial design. LLTS will be delivered through a transcutaneous electrical&#xD;
      nerve stimulation (TENS) device for 15 minutes. HRVdb, HRV and BSEVP will be measured before&#xD;
      and after LLTS and compared.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>15 minutes</time_frame>
    <description>Heart rate variability is a marker of vagus nerve activity and can be easily measured by PC-based ECG software calculating the distance between consecutive R waves on the ECG. Both time domain [standard deviation of normal-to-normal intervals (SDNN), root mean square of successive differences of the normal-to-normal intervals (RMSSD)] and frequency domain [low frequency (LF; 0.04-0.15 Hz), high frequency (HF; 0.15-0.4 Hz), and LF/HF ratio] measures will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mental arithmetic stress test</measure>
    <time_frame>15 minutes</time_frame>
    <description>Mental arithmetic stress test is a measure of sympathetic activity and will be performed by asking the patient to consistently subtract 7 from 500 for a period of 2 minutes. Blood pressure will be measured before and after the test, before and during stimulation and the maximum blood pressure during the test will be the outcome of interest.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Heart Failure, Diastolic</condition>
  <arm_group>
    <arm_group_label>Frequency 20Hz; amplitude 1mA below discomfort threshold</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive tragus stimulation for 15 minutes using the following settings: Frequency 20Hz; amplitude 1mA below discomfort threshold. Continuous ECG will be recorded to assess heart rate variability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Frequency 5Hz; amplitude 1mA below discomfort threshold</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive tragus stimulation for 15 minutes using the following settings: Frequency 5Hz; amplitude 1mA below discomfort threshold. Continuous ECG will be recorded to assess heart rate variability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Frequency 20Hz; amplitude 50% below discomfort threshold</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive tragus stimulation for 15 minutes using the following settings: Frequency 20Hz; amplitude 50% below discomfort threshold. Continuous ECG will be recorded to assess heart rate variability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Frequency 5Hz; amplitude 50% below discomfort threshold</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive tragus stimulation for 15 minutes using the following settings: Frequency 5Hz; amplitude 50% below discomfort threshold. Continuous ECG will be recorded to assess heart rate variability.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Parasym</intervention_name>
    <description>Tragus stimulation</description>
    <arm_group_label>Frequency 20Hz; amplitude 1mA below discomfort threshold</arm_group_label>
    <arm_group_label>Frequency 20Hz; amplitude 50% below discomfort threshold</arm_group_label>
    <arm_group_label>Frequency 5Hz; amplitude 1mA below discomfort threshold</arm_group_label>
    <arm_group_label>Frequency 5Hz; amplitude 50% below discomfort threshold</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients older than 21 year old&#xD;
&#xD;
          2. Healthy volunteers free from diagnosis of AF, heart failure, coronary artery disease&#xD;
             or diseases that affect the autonomic nervous system.&#xD;
&#xD;
          3. Patients with Paroxysmal Atrial Fibrillation&#xD;
&#xD;
          4. Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recent (&lt;6 months) stroke&#xD;
&#xD;
          2. Recent (&lt;6 months) myocardial infarction&#xD;
&#xD;
          3. Heart failure (NYHA class III or IV)&#xD;
&#xD;
          4. Left ventricular ejection fraction &lt;50%&#xD;
&#xD;
          5. Recurrent vaso-vagal syncopal episodes&#xD;
&#xD;
          6. Unilateral or bilateral vagotomy&#xD;
&#xD;
          7. Pregnancy or breast feeding&#xD;
&#xD;
          8. Uncontrolled diabetes or hypertension&#xD;
&#xD;
          9. Inability or unwillingness to understand and/or sign informed consent&#xD;
&#xD;
         10. Any serious disease that affects autonomic nervous system function&#xD;
&#xD;
         11. Any medications that affect autonomic nervous system function&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stavros Stavrakis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karrie Meeks</last_name>
    <phone>4052714742</phone>
    <email>karrie-meeks@ouhsc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Karfonta, RN</last_name>
      <phone>405-271-2229</phone>
      <email>brittany-karfonta@ouhsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karrie Meeks, CCRP</last_name>
      <phone>405-271-2229</phone>
      <email>karrie-meeks@ouhsc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stavros Stavrakis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

